Carlos Reboll Romero is an experienced executive in the pharmaceutical and biotechnology sectors, currently serving as General Manager for Spain at Ypsomed AG since May 2023. Prior roles include Business Unit Director for Oncology Iberia at Ipsen, where Carlos led the unit through challenging changes during the pandemic, achieving double-digit growth and the commercialization of three oncology brands. At Takeda, Carlos secured double-digit growth in the Neuroscience unit amid post-acquisition uncertainty and prepared for the launch of an ADHD product. As Chief of Staff at Shire, strategic initiatives like the PLAN 20K program enhanced revenue. Carlos's extensive background also includes leadership roles at Baxalta, Novo Nordisk, Bristol-Myers Squibb, and Eli Lilly, complemented by an MBA from IESE Business School and a Master of Science in Physics from Universidad Complutense de Madrid.